3145 related articles for article (PubMed ID: 34054840)
1. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
4. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
9. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
10. Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes.
Pu Y; Lu X; Yang X; Yang Y; Wang D; Li M; Guan W; Xu M
J Gastrointest Oncol; 2022 Feb; 13(1):1-12. PubMed ID: 35284129
[TBL] [Abstract][Full Text] [Related]
11. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
12. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
Miao C; Fang X; Chen Y; Zhao Y; Guo Q
Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
[TBL] [Abstract][Full Text] [Related]
13. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
16. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
17. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
18. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.
Zhang C; Liu J; Guo H; Hong D; Ji J; Zhang Q; Guan Q; Ren Q
Bioengineered; 2021 Dec; 12(1):3159-3176. PubMed ID: 34187307
[TBL] [Abstract][Full Text] [Related]
19. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer.
Xu Z; Chen Q; Shu L; Zhang C; Liu W; Wang P
Front Oncol; 2022; 12():970367. PubMed ID: 36003776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]